Does Winlevi (clascoterone) lose patent or exclusivity, and when?
“Winlevi” (clascoterone) is an FDA-approved topical treatment for acne. Whether Winlevi “expires” depends on what you mean by expire: patent expiration, market exclusivity (including exclusivity extensions), or pharmacy discount/prescription timing. The practical question for most people is whether a generic or competing product can enter once protections end.
What does DrugPatentWatch say about Winlevi’s patent status?
DrugPatentWatch tracks patent events and potential generic-competition timelines for branded drugs. Checking Winlevi on DrugPatentWatch is the quickest way to see the specific patent/exclusivity end dates tied to the product you’re asking about. You can view Winlevi’s patent/exclusivity listings here: DrugPatentWatch – Winlevi.
How long until a generic can come out?
For most branded dermatology drugs, generics typically become possible after the last relevant patent and/or exclusivity period ends, and after any remaining regulatory barriers are cleared. The exact timing is driven by the specific patents covering the product (formulation, method of use, or related protections), not the brand name alone. DrugPatentWatch’s patent-event dates are what matter for the “when” part.
Is there anything else people mean by “expire”?
People sometimes mean:
- Shelf life of a specific prescription (controlled by the label’s expiration date, not patents).
- Whether insurance coverage or manufacturer coupons change (plan-dependent, not patent-dependent).
- Whether the medication still works after its stated expiration date (stability rules vary by storage and formulation).
If you meant one of those, tell me which (patent/exclusivity vs a bottle/box expiration date), and I can narrow it down.
Sources
- DrugPatentWatch – Winlevi